EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beta-blocker use and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

Johanna Werk, David Baden, Inna Shaforostova, Jan-Henrik Mikesch, Christian Reicherts, Julia Marx, Georg Lenz, Christoph Schliemann, Matthias Stelljes, Alexander Pohlmann

Annals of Hematology · 25.03.2026 · 105 (4)

DOI: 10.1007/s00277-026-06962-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 25.03.2026. Verfasst von Johanna Werk und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine A, University Hospital Münster, Albert-Schweitzer-Campus 1, Münster, 48149, Germany. Hauptthemen laut MEDLINE: Adrenergic beta-Antagonists, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Münster.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic hematopoietic stem cell transplantation (HSCT) is curative for patients with acute myeloid leukemia (AML) through an immune-mediated graft-versus-leukemia effect, but relapse is common. Studies in solid tumors have shown that adrenergic stress impairs anti-tumor immunity, and that beta-blockade can prolong survival in mice and patients receiving immunotherapy. To this end, we investigated whether beta-blocker use impacts outcomes in AML patients undergoing HSCT. We analyzed the cumulative incidences of relapse (CIR), non-relapse mortality (NRM) and overall survival (OS) in 413 patients with AML who underwent first allogeneic HSCT. A total of 112 patients (27%) received beta-blockers after HSCT. The use of beta-blockers was associated with a lower CIR ( P = 0.024), but with a higher NRM ( P = 0.002); OS did not differ. In multivariable analyses, beta-blocker use emerged as an independent factor associated with CIR ( P = 0.024) and NRM ( P = 0.012), but not OS ( P = 0.353). The occurrence of acute or chronic graft-versus-host disease (GvHD) was not significantly associated with beta-blocker use, but chronic GvHD or organ toxicity was more often the primary cause of death in the beta-blocker group ( P = 0.041). The use of angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARBs) or calcium channel blockers was not significantly associated with outcome. Our study is the first to demonstrate an association between beta-blocker use and post-transplant outcome in AML and supports further investigation of carefully titrated beta-adrenergic blockade as a potential means to influence donor cell immune responses in the transplant setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-AntagonistsHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteHumansMaleFemaleTransplantation, HomologousMiddle AgedAdultGraft vs Host DiseaseTreatment OutcomeAgedYoung AdultAdolescentRetrospective Studies

Stichwörter der Autor:innen

Acute myeloid leukemiaAllogeneic hematopoietic stem cell transplantationBeta-blockerGraft-versus-leukemiaNon-relapse mortality

Substanzen

Adrenergic beta-Antagonists

Autor:innen und Institutionen

  • Department of Medicine A, University Hospital Münster, Albert-Schweitzer-Campus 1, Münster, 48149, Germany.
  • Department of Medicine II, University Hospital Schleswig-Holstein, Lübeck, Germany.
  • Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, 3010, Switzerland.
  • Department of Medicine A, University Hospital Münster, Albert-Schweitzer-Campus 1, Münster, 48149, Germany. alexander.pohlmann@ukmuenster.de.

Förderung

  • Universitätsklinikum Münster

Zitieren

APA

Werk, J., Baden, D., Shaforostova, I., Mikesch, J. H., Reicherts, C., Marx, J., Lenz, G., Schliemann, C., Stelljes, M., & Pohlmann, A. (2026). Beta-blocker use and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Annals of Hematology, 105(4). https://doi.org/10.1007/s00277-026-06962-w

Vancouver

Werk J, Baden D, Shaforostova I, Mikesch JH, Reicherts C, Marx J, et al. Beta-blocker use and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Annals of Hematology. 2026;105(4). doi:10.1007/s00277-026-06962-w

BibTeX
@article{Werk2026,
  author = {Werk, Johanna and Baden, David and Shaforostova, Inna and Mikesch, Jan-Henrik and Reicherts, Christian and Marx, Julia and Lenz, Georg and Schliemann, Christoph and Stelljes, Matthias and Pohlmann, Alexander},
  title = {Beta-blocker use and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {4},
  doi = {10.1007/s00277-026-06962-w}
}
Kostenlos starten →